Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7340769

CC(=O)Nc1cccc2ccc(C(=N)N)cc12.O=C(O)C(F)(F)F

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLAU P00749 8/20 0.64
F2 P00734 9/20 0.49
KLK1 P06870 7/20 0.49
PLG P00747 5/20 0.49
PLAT P00750 5/20 0.49
PRSS1 P07477 4/20 0.49
TRPV1 Q8NER1 2/20 0.45
TMPRSS6 Q8IU80 2/20 0.45
F10 P00742 1/20 0.44
KLK5 Q9Y337 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
PLA2G2D Q9UNK4 1/20 0.43
KLKB1 P03952 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28742391 0.91 PLAU (0.75) PLAUF2KLK1PLGPLAT
Trifluoroacetic Acid SCHEMBL7456113 0.90 PLAU (0.63) PLAUF2KLK1PLGPLAT
Trifluoroacetic Acid SCHEMBL7343433 0.84 PLAU (0.63) PLAUF2KLK1PLGPLAT
SCHEMBL7335327 0.82 PLAU (0.72) PLAUF2KLK1PLGPLAT
SCHEMBL8755640 0.80 PLAU (0.55) PLAUTRPV1KDM4EALDH1A1MAPT
SCHEMBL7335597 0.80 PLAU (0.74) PLAUF2KLK1PLGPLAT
SCHEMBL7456120 0.80 PLAU (0.70) PLAUF2KLK1PLGPLAT
Trifluoroacetic Acid SCHEMBL7337751 0.79 PLAU (0.65) PLAUF2KLK1PLGPLAT
Trifluoroacetic Acid SCHEMBL7335932 0.79 PLAU (0.57) PLAUKDM4EALDH1A1MAPTHPGD
SCHEMBL7336808 0.78 PLAU (0.71) PLAUF2KLK1PLGPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP claimed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885F2 38/4885KLK1 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.